Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels, preventing nerve impulse transmission and producing anesthesia. Phenylephrine stimulates alpha‑1 adrenergic receptors on the iris dilator muscle, causing contraction and pupil enlargement. Tropicamide blocks muscarinic receptors in the iris sphincter muscle, leading to relaxation and further dilation. Together they create a fast, sustained mydriatic and anesthetic effect.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific surgical procedure and patient characteristics. It is administered as an intracameral injection in a sterile manner, and the exact volume or concentration is prescribed by the treating clinician.

Safety of Mydrane in pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the prescribing physician.

To order Mydrane, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mydrane combines a local anesthetic (lidocaine) with two mydriatics (phenylephrine and tropicamide) in a single intracameral formulation, offering simultaneous anesthesia and dilation. Separate agents may require multiple applications and longer onset times. Mydrane’s combined approach can reduce procedural steps and provide more predictable pupil dilation during surgery.

Mydrane should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility and potency.

Mydrane is administered by a qualified ophthalmic surgeon as a sterile intracameral injection directly into the anterior chamber of the eye. The procedure is performed under aseptic conditions immediately before the intended intra‑ocular surgery.

Serious risks include severe allergic reactions such as anaphylaxis, persistent or prolonged mydriasis, sustained elevation of intraocular pressure, corneal endothelial toxicity, endophthalmitis, and retinal toxicity. Prompt recognition and appropriate management of these events are essential.

Mydrane should not be used in patients with known hypersensitivity to lidocaine, phenylephrine, tropicamide, or any excipients. Caution is advised for individuals with narrow‑angle glaucoma, uncontrolled hypertension, or those taking systemic alpha‑adrenergic agonists. The prescribing clinician must evaluate each patient’s suitability before use.